Neurocrine Biosciences, Inc.
NBIX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $2.86B | $2.36B | +21.4% |
| Operating income | $619M | $570M | +8.5% |
| Net income | $479M | $341M | +40.2% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $1.12B | $795M | +41.2% |
| Operating income | $331M | $239M | +38.6% |
| Net income | $206M | $210M | −1.4% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Neurocrine's revenue in FY2025?
- $2.86B in FY2025 (Fiscal year ended Dec 31, 2025), +21.4% vs $2.36B a year earlier, per its 10-K filed Feb 2026.
- Was Neurocrine profitable in FY2025?
- Yes: net income was $479M and operating income $619M in FY2025.
- What was Neurocrine's revenue in Q3 2026?
- $1.12B (+41.2% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.